Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

How DNA mutations hijack blood-forming stem cells

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Every day your marrow copies billions of cells, and copying is never perfect. Most errors are harmless, and most of the rest kill the cell that carries them.

Leukemia is what happens when errors land on a particular short list of genes, in a particular order, in a cell that lives long enough to pass them on.

Related pages: Leukemia (blood cancer)

The bottom line

What we know
  • Leukemia arises from mutations in blood-forming stem or progenitor cells.
  • The mutations that matter fall into a few functional groups: grow, do not mature, do not die.
  • Many leukemias are driven by chromosomal translocations, where two chromosomes break and swap pieces, creating a fusion gene.
  • Most cases need several mutations accumulating over time, not one.
What is still open
  • Why some people with pre-leukemic mutations never develop leukemia and others do.
  • Whether the earliest mutated cells could be targeted before disease develops.

The story, step by step

  1. 1. What a driver does ()
  2. 2. Translocations ()
  3. 3. The usual suspects ()
  4. 4. In order ()
  5. 5. Not inherited ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Three broken instructions

Lab or animal study

What happens

Of the thousands of genetic changes found in a leukemic cell, only a handful actually drive the disease. They tend to break the same three instructions.

What the research shows

  • Divide when told to stop: a growth signal gets jammed permanently on.
  • Mature into a working cell: the maturation program is blocked, leaving the cell stuck as a blast.
  • Die on schedule: the self-destruct program, apoptosis, is disabled, so cells that should be cleared accumulate.
  • A cell that has all three has every ingredient of cancer. Most normal cells have safeguards against each one.

Why it matters

Nearly every targeted leukemia drug works by restoring one of these three instructions, so the categories are not academic.

What's still uncertain

  • Distinguishing the handful of driver mutations from the many passenger mutations in a given person's cells is genuinely difficult.

Read more

Next: Translocations

Part 2 of 5

Two chromosomes break and swap

Lab or animal study

What happens

The clearest example in all of cancer biology is a chromosomal translocation.

What the research shows

  • In chronic myeloid leukemia, chromosomes 9 and 22 break and exchange pieces. The result is the Philadelphia chromosome.
  • The join creates a fusion gene, BCR-ABL1, which makes a protein that is a growth-signal enzyme stuck permanently in the on position.
  • This was the first consistent chromosomal abnormality ever linked to a human cancer, identified in Philadelphia in 1960.
  • In childhood acute lymphoblastic leukemia, translocations such as ETV6-RUNX1 do something similar, jamming the maturation program instead.

Why it matters

A single, identifiable, always-on enzyme turned out to be a perfect drug target, which is the entire reason CML treatment changed so dramatically.

What's still uncertain

  • Why translocations occur where they do, and what makes certain chromosome regions fragile, is only partly understood.

Read more

Next: The usual suspects

Part 3 of 5

The genes that come up again and again

Lab or animal study

What happens

Sequencing thousands of cases produced a recurring cast.

What the research shows

  • FLT3: a growth receptor that becomes permanently active in a substantial share of acute myeloid leukemia, and a target for several drugs.
  • NPM1: one of the most common mutations in AML, and in the absence of other bad markers, one associated with a better outlook.
  • IDH1 and IDH2: metabolic enzymes that, when mutated, produce an abnormal molecule that blocks maturation. Inhibitors exist.
  • DNMT3A, TET2 and ASXL1: genes that control which other genes are switched on. These often appear earliest.
  • TP53: the master damage-control gene. When it is lost, the cell stops responding to damage signals, and the leukemia is harder to treat.

Why it matters

Which of these a person carries affects treatment choice and outlook more than almost anything else, which is why the genetic panel is run on everyone.

What's still uncertain

  • The list keeps growing, and the significance of some newly found mutations is not yet established.

Read more

Next: In order

Part 4 of 5

Leukemia is built up, not switched on

Lab or animal study

What happens

Most leukemias do not appear in one step.

What the research shows

  • As people age, blood stem cells accumulate mutations. In some, one mutated clone expands and takes over a measurable share of blood production.
  • That state is called clonal hematopoiesis of indeterminate potential, or CHIP. It is common over the age of seventy, and most people with it never develop leukemia.
  • Carrying CHIP does raise the risk of a blood cancer later, and also of heart disease, which was an unexpected finding.
  • Childhood ALL often starts differently: in many cases the first mutation happens before birth, and twin studies show the same pre-leukemic clone in both twins when one later develops the disease.

Why it matters

This is why leukemia is mostly a disease of older adults, with one striking peak in early childhood that follows different rules.

What's still uncertain

  • No treatment for CHIP exists, and there is no evidence that finding it incidentally improves outcomes.

Read more

Next: Not inherited

Part 5 of 5

What people most often get wrong

Review of many studies

What happens

Almost everyone newly diagnosed asks whether they passed it on or inherited it.

What the research shows

  • The great majority of leukemia mutations are acquired during a person's life, not inherited. They are present in the leukemic cells only, not in sperm or eggs.
  • A small number of inherited syndromes do raise risk substantially, including Fanconi anemia, Li-Fraumeni syndrome, Down syndrome and some familial platelet disorders.
  • Down syndrome raises risk through a specific route involving the extra copy of chromosome 21 and mutations in a gene called GATA1, not through a defect in DNA repair.
  • Leukemia is not contagious, and nothing a parent did or did not do causes childhood leukemia.

Why it matters

If several close relatives have had blood cancers at young ages, that is worth raising with a doctor. Otherwise an individual case is almost never inherited.

What's still uncertain

  • Inherited predisposition is probably underdiagnosed, and testing criteria are still being refined.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.